NCT06586320

Quantification of Parkinson's Disease Patients As a Biomarker for Classification, Prediction and Response to Treatment

Enrolling by Invitation
NAAges 18+InterventionalDiagnostic
Stardots AB
~40 participants
Updated 2025-02-20 on ClinicalTrials.gov
What's tested:150% of their routine home dopaminergic medications dose right in the clinicEvaluation of mathematical models

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Quantification of current IPD motor symptoms using kinetic tremor and Dyskinesia test
Measured over Day 1
Parkinson Disease

NCT06586320

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Dartmouth Hitchcock medical center

    Manchester, New Hampshireno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Anas Hannoun, MD · PRINCIPAL_INVESTIGATOR · Dartmouth Hitchcock medical center, Manchester

This trial hasn't published a contact. View it on ClinicalTrials.gov

  • Quantification of current IPD motor symptoms using kinetic tremor and Dyskinesia testDay 1

    ANLIVA® Hand Movement score of kinetic tremor test and dyskinesia test will be measured. Measurements are done on subjects upper limb movements. SD score of kinetic tremor test and dyskinesia test will be assessed by assessors. SD is acronym for Stardots-Dartmouth score. The SD score will be used to benchmark the ANLIVA® device assessments as a nonreference standard. Minimum value is 0; maximum value is 4. A higher value on the SD score means more movement disorder.